|
- Johnson Johnsons dual-targeting CAR T-cell therapy shows encouraging . . .
Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19 CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R R LBCL) who have not been previously treated with CAR T-cell therapy
- Johnson Johnson’s dual-targeting CAR T-cell therapy shows encouraging . . .
MILAN (June 13, 2025) – Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19 CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R R LBCL) who have not been previously
- Our leadership team - Johnson Johnson
Joseph J Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson Johnson Joe serves as a member of the company’s Executive Committee, playing a strategic role in the overall management of the organization and leading the development and execution of the business’ global long-term financial strategy
- Johnson Johnson showcases latest advancements in cancer innovation . . .
†See the NCCN Guidelines for detailed recommendations, including other treatment options ‡ The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories § The NCCN Content does not constitute medical advice
- Johnson Johnson
WARNING NOTICE: This system is restricted solely to Johnson Johnson users for legitimate business only The actual or attempted unauthorized access, use or modification of this system is strictly prohibited by Johnson Johnson Unauthorized users are subject to Company disciplinary proceedings and or criminal and civil penalties under state, federal or other applicable domestic and foreign
- Explore current job openings | Johnson Johnson | Johnson Johnson . . .
Explore exciting job openings at J J Search global roles in healthcare and join a team committed to innovation, growth and a healthier future for all
- Locations | Johnson Johnson Careers
Learn about the regions and countries where J J operates and explore career opportunities, search for jobs and apply to join us wherever you are in the world
- portman. jnj. com
WARNING NOTICE: This system is restricted solely to Johnson Johnson users for legitimate business only The actual or attempted unauthorized access, use or modification of this system is strictly prohibited by Johnson Johnson Unauthorized users are subject to Company disciplinary proceedings and or criminal and civil penalties under state, federal or other applicable domestic and foreign
|
|
|